CD86 and breast cancer: Finally, CD86 molecule (CD86) was identified by using several bioinformatics and experimental assays and regarded as an immune-related prognostic biomarker in BC, which had great effects for assessing prognosis of BC patients and might be a novel target for immunotherapy.